{"id":"W4288034414","doi":"10.1093/oncolo/oyac142","title":"Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"The Oncologist","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Merck Sharp and Dohme; Eisai; Merck","keywords":"Lenvatinib; Medicine; Everolimus; Renal cell carcinoma; Quality of life (healthcare); Internal medicine; Oncology; Adverse effect; Clinical trial; Sorafenib; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001014355,0.0002082284,0.0009779506,0.0001111695,0.0001367567,0.000004434271,0.0001421121,0.00003488358,0.00003124402],"category_scores_gemma":[0.0001163083,0.0001115287,0.0001020279,0.0002945014,0.0001944323,0.00002827081,0.00006732144,0.0002219928,3.171092e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006617359,"about_ca_system_score_gemma":0.0004071665,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006910624,"about_ca_topic_score_gemma":0.001824836,"domain_scores_codex":[0.9974795,0.0006000987,0.0009191945,0.0002631671,0.0004450581,0.000292975],"domain_scores_gemma":[0.9975726,0.0007628687,0.00107477,0.0003777616,0.0001273916,0.00008462877],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009079765,0.002035048,0.982149,0.0004045064,0.0001294676,0.00001628256,0.002102879,0.0009412494,0.002183711,0.0001622295,0.00006637048,0.0007294698],"study_design_scores_gemma":[0.02031735,0.01663736,0.9534643,0.00006557672,0.0001620247,0.00000974951,0.00142553,0.0002433054,0.00745968,0.00008749611,0.000008834999,0.0001188436],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944321,0.0003896697,0.00003105416,0.002225783,0.00002542898,0.002445656,0.00004515377,0.00002863522,0.0003765119],"genre_scores_gemma":[0.9987729,0.000005903974,0.0002912999,0.0001624315,0.000007319266,0.000342337,0.0001096863,0.00002486814,0.0002833148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02868478,"threshold_uncertainty_score":0.9997025,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06752936432084708,"score_gpt":0.3277357303072121,"score_spread":0.260206365986365,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}